Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide + RT in Anaplastic Oligodendroglioma (RTOG 0131)
NCT00033280Phase 2Completed
- Sponsor
- NRG Oncology
- Start
- Jul 2002
- Primary completion
- Apr 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of temozolomide in anaplastic oligodendroglioma (AO), anaplastic oligoastrocytoma (AMOA), sponsored by NRG Oncology. Started Jul 2002; status: completed.
02
Drugs
temozolomide
03
Conditions
anaplastic oligodendroglioma (AO)anaplastic oligoastrocytoma (AMOA)
Beyond the preview
Go deeper on NCT00033280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00033280.